Worth reading
64In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
24.2
Year-on-year change in net sales (%)Wording
Definitive
How definitive the wording is.Contents of this document
Earnings presentationSecond quarter of the fiscal year ending March 20278 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥7,236 millions+24.2%
Operating profit¥1,513 millions+19.9%
Ordinary income¥1,506 millions+20.3%
Net income¥1,505 millions-7.1%
Results for the three months of the current quarterA graph showing quarterly trends in revenue, recurring revenue, one-off revenue, recurring gross profit and operating profit
Full-year earnings forecast
Net Sales
¥14,400 millions
Operating profit
¥3,100 millions
Ordinary income
¥3,100 millions
Profit attributable to owners of parent for the quarter
¥3,100 millions
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales50%
Operating profit49%
Ordinary income49%
Profit attributable to owners of parent for the quarter49%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Operating profit and ordinary profit are also progressing steadily against the full-year earnings forecasts.New initiatives
- Improving the efficiency and productivity of internal operations and reducing SG&A expenses through the use of AI
Key KPIsA metric the company considers important as a management benchmark.
- Number of EPARK Okusuri Techō downloads800 10,000 downloads
- Number of contracted facilities56,131 FacilityYear on year against the same period last year+19.5%
- Number of facilities using multiple products12,093 FacilityYear on year against the same period last year+48.8%
- Cross-selling rate21.5 %Year on year against the same period last year+4.2pt
- ARPU¥15.1 thousandYear on year against the same period last year+8.9%
- Number of prescriptions accepted online2,033 thousand transactionsYear on year against the same period last year+320 thousand
- Number of facilities with healthcare automation systems24,888 projectsYear on year against the same period last year+935 facilities
Unit price and quantity metricsThese figures show sales broken down by price and volume.
- ARPU¥15.1 thousandYear on year against the same period last year+8.9%
- Number of prescriptions accepted online2,033 thousand transactionsYear on year against the same period last year+320 thousand
Segment results
Healthcare Automation business
Net Sales
¥3,170 millions+35.7%
Gross profit from recurring revenue
¥1,260 millions+65.2%
みんなのお薬箱 business
Net Sales
¥1,900 millions+11.8%
Gross profit from recurring revenue
¥740 millions-1.0%
Core Systems business
Net Sales
¥2,010 millions+18.2%
Gross profit from recurring revenue
¥370 millions+45.6%
Market Size / Share
- The Company's share of online prescription acceptance2.1 %
- The Company's share of pharmacies39.2 %
- Market size by number of prescriptions8.9 100 million prescriptions
- Number of pharmacies6.3 10,000 facilities
Number of employees
1,314 people
Acquisition of treasury shares
¥500 million
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Second quarter of the fiscal year ending March 2027 |
| Net Sales | ¥7,236 millions (YoY +24.2%) |
| Operating profit | ¥1,513 millions (YoY +19.9%) |
| Ordinary income | ¥1,506 millions (YoY +20.3%) |
| Net income | ¥1,505 millions (YoY -7.1%) |
| Results for the three months of the current quarter | A graph showing quarterly trends in revenue, recurring revenue, one-off revenue, recurring gross profit and operating profit |
| Full-year earnings forecast | Net Sales ¥14,400 millions / Operating profit ¥3,100 millions / Ordinary income ¥3,100 millions / Profit attributable to owners of parent for the quarter ¥3,100 millions |
| Progress against full-year forecast | Net Sales 50% / Operating profit 49% / Ordinary income 49% / Profit attributable to owners of parent for the quarter 49% |
| Self-assessment against the plan | Operating profit and ordinary profit are also progressing steadily against the full-year earnings forecasts. |
| Segment results | Healthcare Automation business Net Sales ¥3,170 millions (YoY +35.7%) / Gross profit from recurring revenue ¥1,260 millions (YoY +65.2%) / みんなのお薬箱 business Net Sales ¥1,900 millions (YoY +11.8%) / Gross profit from recurring revenue ¥740 millions (YoY -1.0%) / Core Systems business Net Sales ¥2,010 millions (YoY +18.2%) / Gross profit from recurring revenue ¥370 millions (YoY +45.6%) / Wellness Platform business Not disclosed |
| Key KPIs | Indicator name Number of EPARK Okusuri Techō downloads / Value 800 10,000 downloads / Year on year against the same period last year Not disclosed, Indicator name Number of contracted facilities / Value 56,131 Facility / Year on year against the same period last year +19.5%, Indicator name Number of facilities using multiple products / Value 12,093 Facility / Year on year against the same period last year +48.8%, Indicator name Cross-selling rate / Value 21.5 % / Year on year against the same period last year +4.2pt, Indicator name ARPU / Value ¥15.1 thousand / Year on year against the same period last year +8.9%, Indicator name Number of prescriptions accepted online / Value 2,033 thousand transactions / Year on year against the same period last year +320 thousand, Indicator name Number of facilities with healthcare automation systems / Value 24,888 projects / Year on year against the same period last year +935 facilities |
| Unit price and quantity metrics | Indicator name ARPU / Value ¥15.1 thousand / Year on year against the same period last year +8.9%, Indicator name Number of prescriptions accepted online / Value 2,033 thousand transactions / Year on year against the same period last year +320 thousand |
| Number of employees | Value 1,314 people / Change during the period Not disclosed |
| Acquisition of treasury shares | Amount ¥500 million / Number of Shares Not disclosed / Period Not disclosed |
| Market Size / Share | Indicator name The Company's share of online prescription acceptance / Value 2.1 %, Indicator name The Company's share of pharmacies / Value 39.2 %, Indicator name Market size by number of prescriptions / Value 8.9 100 million prescriptions, Indicator name Number of pharmacies / Value 6.3 10,000 facilities |
| New initiatives | Improving the efficiency and productivity of internal operations and reducing SG&A expenses through the use of AI |
Items this document does not state (14)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesBreakdown of Factors Affecting the ChangeNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue and profit increased due to the accumulation of recurring revenue in each business, increases in the number of prescriptions accepted online and affiliated facilities, the consolidation effects of Medi-Web Co., Ltd. and Techno Network Co., Ltd., and the acquisition of Moinet System. The decline in net profit resulted from the reversal of a temporary decrease of approximately ¥600 million in tax expenses in the previous year, when additional deferred tax assets were recognized in connection with a capital reduction.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.